Vuk-Pavlovic S - Search Results

1

Markovic SN, Erickson LA, Flotte TJ, Kottschade LA, McWilliams RR, Jakub JW, Farley DR, Tran NV, Schild SE, Olivier KR, Vuk-Pavlovic S, Sekulic A, Weenig RH, Pulido JS, Quevedo JF, Vile RG, Wiseman GA, Stoian I, Pittelkow MR; Melanoma Study Group of the Mayo Clinic Cancer Center. Markovic SN, et al. G Ital Dermatol Venereol. 2009 Feb;144(1):1-26. G Ital Dermatol Venereol. 2009. PMID: 19218908 Review.

2

Malignant melanoma in the 21st century: the emerging molecular landscape.

Sekulic A, Haluska P Jr, Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, Salomao DR, Thorland EC, Vile RG, Swanson DL, Pockaj BA, Laman SD, Pittelkow MR, Markovic SN; Melanoma Study Group of Mayo Clinic Cancer Center. Sekulic A, et al. Mayo Clin Proc. 2008 Jul;83(7):825-46. doi: 10.4065/83.7.825. Mayo Clin Proc. 2008. PMID: 18613999 Free PMC article. Review.

3

Immune cells in the human choroid.

Ezzat MK, Hann CR, Vuk-Pavlovic S, Pulido JS. Ezzat MK, et al. Br J Ophthalmol. 2008 Jul;92(7):976-80. doi: 10.1136/bjo.2007.129742. Br J Ophthalmol. 2008. PMID: 18577650

4

Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma.

Markovic SN, Dietz AB, Greiner CW, Maas ML, Butler GW, Padley DJ, Bulur PA, Allred JB, Creagan ET, Ingle JN, Gastineau DA, Vuk-Pavlovic S. Markovic SN, et al. J Transl Med. 2006 Aug 15;4:35. doi: 10.1186/1479-5876-4-35. J Transl Med. 2006. PMID: 16911798 Free PMC article.

5

Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma.

Dietz AB, Padley DJ, Butler GW, Maas ML, Greiner CW, Gastineau DA, Vuk-Pavlović S. Dietz AB, et al. Cytotherapy. 2004;6(6):563-70. doi: 10.1080/14653240410005357-1. Cytotherapy. 2004. PMID: 15773024

6

Biomathematical modeling and cancer immunotherapy: report of the workshop held at Bol, Island of Brač, Croatia, 20-21 June 2011.

Vuk-Pavlović S. Vuk-Pavlović S. Cytotherapy. 2012 Feb;14(2):144-6. doi: 10.3109/14653249.2011.623694. Epub 2011 Oct 24. Cytotherapy. 2012. PMID: 22017451

7

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlović S. Burch PA, et al. Prostate. 2004 Aug 1;60(3):197-204. doi: 10.1002/pros.20040. Prostate. 2004. PMID: 15176049 Clinical Trial.

8

Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.

Vuk-Pavlović S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, Dietz AB. Vuk-Pavlović S, et al. Prostate. 2010 Mar 1;70(4):443-55. doi: 10.1002/pros.21078. Prostate. 2010. PMID: 19902470 Free PMC article.

9

Maturation of human monocyte-derived dendritic cells studied by microarray hybridization.

Dietz AB, Bulur PA, Knutson GJ, Matasić R, Vuk-Pavlović S. Dietz AB, et al. Biochem Biophys Res Commun. 2000 Sep 7;275(3):731-8. doi: 10.1006/bbrc.2000.3372. Biochem Biophys Res Commun. 2000. PMID: 10973791

10

Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact on transgene expression.

Dietz AB, Bulur PA, Brown CA, Pankratz VS, Vuk-Pavlovic S. Dietz AB, et al. Gene Ther. 2001 Mar;8(5):419-23. doi: 10.1038/sj.gt.3301406. Gene Ther. 2001. PMID: 11313819

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters